| Popis: |
Table 1A. 12, 24 and 36 month transition probabilities for incident HPV 16, 18, 31, 33, 35, 45, 52, 58 and 59 infections without adjudication of CIN lesions positive for multiple HPV types. Table 1B. 12 and 24 month transition probabilities for incident HPV 16, 18, 31, 45, 52 and 58 infected CIN 1 lesions without adjudication of CIN lesions positive for multiple HPV types. Table 2A. Prevalence of HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 infections in CIN 1, CIN 2 and CIN 3 lesions (data derived from placebo arms of all Phase III trials)Table 2B. Prevalence of HPV 6, 11, 16, 18 with and without other tested HPV types* in CIN 1, CIN 2 and CIN 3 lesions (data derived from placebo arms of all Phase III trials). Table 3A. Distribution of HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 in CIN 1, CIN 2 and CIN 3 lesions testing positive for a concordant HPV type as observed in a prior or concurrent incident HPV 16/18/31/33/35/45/52/58/59 infection. Table 3B. Distribution of HPV types 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 in CIN 2 and CIN 3 lesions testing positive for a concordant HPV type as observed in a prior incident HPV 16/18/31/33/35/45/52/58/59 infected CIN 1 lesion. |
